Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

93 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Pancreatic Cancer NCT00088894 - EQ-5D FORM Pancreatic Cancer CALGB NCT00088894

- 02.07.17 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache
Itemgruppen: Header, EQ-5D
CALGB: EQ-5D FORM Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D602C703-1CB1-3D8F-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Quality of Life - Brief Pain Inventory - 2031356v3.0 - Brief Pain Inventory

- 09.01.15 - 1 Formular, 2 Itemgruppen, 23 Datenelemente, 1 Sprache
Itemgruppen: Header, CCRR MODULE
Brief Pain Inventory A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AE65F8E1-704E-30A0-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Follow-Up - Hematology/Chemistry Form - 2048132v3.0 - Hematology/Chemistry Form

- 21.01.15 - 1 Formular, 2 Itemgruppen, 31 Datenelemente, 1 Sprache
Itemgruppen: Header, Hematology and Chemistry
Hematology/Chemistry Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D4877-9B57-427A-E034-0003BA0B1A09

On-Study - Resectable Pancreatic Cancer - On-Study Form - 2020205v2.31 - Resectable Pancreatic Cancer - On-Study Form

- 08.01.15 - 1 Formular, 3 Itemgruppen, 25 Datenelemente, 1 Sprache
Itemgruppen: CRF Header, PANCREATIC: FORM ADMINISTRATION, PANCREATIC: DISEASE DESCRIPTION
Resectable Pancreatic Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A9AA-3FA4-E034-080020C9C0E0

On-Study - Unresectable Pancreatic Cancer - On-Study Form - 2020206v2.31 - Unresectable Pancreatic Cancer - On-Study Form

- 08.01.15 - 1 Formular, 3 Itemgruppen, 25 Datenelemente, 1 Sprache
Itemgruppen: CRF Header, PANCREATIC: FORM ADMINISTRATION, PANCREATIC: DISEASE DESCRIPTION
Unresectable Pancreatic Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A9AC-3FA4-E034-080020C9C0E0

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27.11.24 - 5 Formulare, 1 Itemgruppe, 1 Datenelement, 1 Sprache
Itemgruppe: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Itemgruppe 5 Datenelemente

pht004835.v1.p1

1 Itemgruppe 5 Datenelemente

pht004836.v1.p1

1 Itemgruppe 16 Datenelemente

pht004837.v1.p1

1 Itemgruppe 5 Datenelemente

Baseline Laboratory test form pancreatic cancer SWOG S0205 NCT00075686

- 24.09.15 - 1 Formular, 2 Itemgruppen, 35 Datenelemente, 1 Sprache
Itemgruppen: Header, BASELINE LAB TEST RESULTS
BASELINE LABORATORY TEST RESULT FORM - 2307541v3.0 SOUTHWEST ONCOLOGY GROUP S0205 BASELINE LABORATORY TEST RESULT FORM S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F2FD3D46-E071-663C-E034-0003BA3F9857

dbGaP phs000648 Pancreatic Cancer Case-Control Association Study - pht004578.v1.p1

- 25.11.22 - 5 Formulare, 1 Itemgruppe, 5 Datenelemente, 1 Sprache
Itemgruppe: pht004578
Principal Investigator: Alison P. Klein, Johns Hopkins School of Medicine, Baltimore MD, USA MeSH: Pancreatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000648 Pancreatic cancer is the 4th leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000 participants from 9 studies of pancreatic cancer, to conduct a GWAS of pancreatic cancer. The studies were drawn from the Pancreatic Cancer Case-Control consortium and include case-control studies from the United States, Europe and Australia. Sites include: Johns Hopkins National Familial Pancreas Tumor Registry, Mayo Clinic Biospecimen Resource for Pancreas Research, Ontario Pancreas Cancer Study (OPCS), Yale University, MD Anderson Case Control Study, Queensland Pancreatic Cancer Study, University of California San Francisco Molecular Epidemiology of Pancreatic Cancer Study, International Agency of Cancer Research and Memorial Sloan Kettering Cancer Center

pht004580.v1.p1

1 Itemgruppe 5 Datenelemente

pht004579.v1.p1

1 Itemgruppe 5 Datenelemente

Eligibility

1 Itemgruppe 1 Datenelement

pht004577.v1.p1

1 Itemgruppe 4 Datenelemente

Pancreatic Cancer NCT00733746 Registration - ACOSOG-Z5041 Registration Worksheet - 2921129v1.0 - ACOSOG-Z5041 Registration Worksheet

- 20.09.21 - 1 Formular, 4 Itemgruppen, 34 Datenelemente, 1 Sprache
Itemgruppen: Header Module, Eligibility Criteria, Diagnosis and Therapy, Specimen Banking Consent
ACOSOG-Z5041 Registration Worksheet Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6F3D4C5B-FB42-7755-E040-BB89AD432E97

On-Study - Curative Treatment for Head and Neck Cancer - On-Study Form - 2268312v3.0 - Curative Treatment for Head and Neck Cancer - On-Study Form

- 20.09.21 - 1 Formular, 5 Itemgruppen, 48 Datenelemente, 1 Sprache
Itemgruppen: CRF Header, Head & Neck: Form Administration, Head & Neck: Patient Assessment, Head & Neck: Disease Description, Head & Neck: Prior Health History - Curative
Curative Treatment for Head and Neck Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D4976276-569A-5CEB-E034-0003BA12F5E7

Pancreatic Cancer NCT00733746 Registration - Z5041 - OPEN Enrollment Form - 3013792v1.0 - Z5041 - OPEN Enrollment Form

- 17.09.21 - 1 Formular, 3 Itemgruppen, 44 Datenelemente, 1 Sprache
Itemgruppen: Demography Section, General Information, Eligibility Checklist
Z5041 - OPEN Enrollment Form Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7FFA1514-8347-A58F-E040-BB89AD4376E5

CALGB: C-1001 NEW PRIMARY CANCER FORM [80303] NCT00088894

- 21.06.15 - 1 Formular, 4 Itemgruppen, 15 Datenelemente, 1 Sprache
Itemgruppen: Header, Patient demographics, NEW PRIMARY CANCER ASSESSMENT, Comments
CALGB: C-1001 NEW PRIMARY CANCER FORM [80303] NCT00088894 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5FEE4C9-F395-6F2C-E034-0003BA12F5E7

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video